Marina Bárcena‐Varela, Stefano Caruso, Susana Llerena, Gloria Álvarez‐Sola, Iker Uriarte, M. Ujue Latasa, Raquel Urtasun, Sandra Rebouissou, Laura Alvarez, Maddalen Jimenez, Eva Santamaría, Carlos Rodriguez‐Ortigosa, Giuseppe Mazza, Krista Rombouts, Edurne San José‐Eneriz, Obdulia Rabal, Xabier Agirre, Maria Iraburu, Alvaro Santos‐Laso, Jesus M. Banales, Jessica Zucman‐Rossi, Felipe Prósper, Julen Oyarzabal, Carmen Berasain, Matías A. Ávila, Maite G.

Changhui Zhou, Weihua Wang, Ying Mu – 16 July 2018

Donghee Kim, Andrew A. Li, Brandon J. Perumpail, Chiranjeevi Gadiparthi, Won Kim, George Cholankeril, Jeffrey S. Glenn, Stephen A. Harrison, Zobair M. Younossi, Aijaz Ahmed – 16 July 2018 – With recent improvements in the treatment of end‐stage liver disease (ESLD), a better understanding of the burden of cirrhosis and hepatocellular carcinoma (HCC) is needed in the United States. A population‐based study using the US Census and national mortality database was performed.

Sih‐Han Liao, Tung‐Hung Su, Yung‐Ming Jeng, Po‐Chin Liang, Ding‐Shinn Chen, Chien‐Hung Chen, Jia‐Horng Kao – 16 July 2018 – Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer‐related deaths worldwide. Sarcomatoid HCC is a rare histological subtype of HCC with largely unclear clinical manifestations and outcomes. We evaluated the clinical manifestations and outcomes of patients with sarcomatoid HCC.

Chia‐Ming Chu, Yun‐Fan Liaw – 16 July 2018

Anne S. Henkel – 13 July 2018

Juan Jovel, Zhen Lin, Sandra O'keefe, Steven Willows, Weiwei Wang, Guangzhi Zhang, Jordan Patterson, Carlos Moctezuma‐Velázquez, David J. Kelvin, Gane Ka‐Shu Wong, Andrew L. Mason – 12 July 2018 – Understanding the heterogeneity of dysregulated pathways associated with the development of hepatocellular carcinoma (HCC) may provide prognostic and therapeutic avenues for disease management.

Devika Kapuria, Varun K. Takyar, Ohad Etzion, Pallavi Surana, James H. O'Keefe, Christopher Koh – 6 July 2018 – Nonalcoholic fatty liver disease (NAFLD) is becoming common in the United States and throughout the world and can progress to cirrhosis, hepatocellular carcinoma, and death. There is a strong association between coronary artery disease and NAFLD due to common risk factors, such as metabolic syndrome, obesity, and diabetes mellitus.

5 July 2018

5 July 2018